Slingshot members are tracking this event:
Tal Medical (PTCHF) Completes Phase 2 Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
- Source Link:
Slingshot Insights Explained
Oct 11, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2, Dose Optimization Study, Trial Completion, Low Field Magnetic Stimulation, Lfms, Treatment-resistant Depression, Trd, Solidd